{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:41:52Z","timestamp":1792237312168,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s13318-023-00872-2","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T04:49:16Z","timestamp":1703047756000},"page":"101-109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of Hydroxychloroquine as a Perpetrator on Cytochrome P450 (CYP) 3A and CYP2D6 Activity with Microdosed Probe Drugs in Healthy Volunteers"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3005-0546","authenticated-orcid":false,"given":"Felicitas","family":"Stoll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Mikus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Czock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen J.","family":"Meyer-T\u00f6nnies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja S.","family":"G\u00fcm\u00fcs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mladen","family":"Tzvetkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Burhenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter E.","family":"Haefeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,20]]},"reference":[{"issue":"1","key":"872_CR1","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1038\/s41467-021-22446-z","volume":"12","author":"C Axfors","year":"2021","unstructured":"Axfors C, et\u00a0al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021;12(1):2349.","journal-title":"Nat Commun"},{"key":"872_CR2","doi-asserted-by":"crossref","unstructured":"Seguin DJ, et al. Polypharmacy and potentially inappropriate medication use in older adults with systemic lupus erythematosus.\nArthritis Care Res (Hoboken). 2023;75:356\u2013364.","DOI":"10.1002\/acr.24766"},{"issue":"3","key":"872_CR3","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/0897190019869158","volume":"34","author":"APM Gomides","year":"2021","unstructured":"Gomides APM, et\u00a0al. High levels of polypharmacy in rheumatoid arthritis\u2014a challenge not covered by current management recommendations: data from a large real-life study. J Pharm Pract. 2021;34(3):365\u201371.","journal-title":"J Pharm Pract"},{"key":"872_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.573542","volume":"7","author":"JD Jack","year":"2020","unstructured":"Jack JD, et\u00a0al. Polypharmacy in Middle-European rheumatoid arthritis-patients: a retrospective longitudinal cohort analysis with systematic literature review. Front Med (Lausanne). 2020;7: 573542.","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"872_CR5","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1136\/annrheumdis-2018-213687","volume":"77","author":"NMT Roodenrijs","year":"2018","unstructured":"Roodenrijs NMT, et\u00a0al. Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. Ann Rheum Dis. 2018;77(12):1705\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"872_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12888-017-1234-1","volume":"17","author":"L Zhang","year":"2017","unstructured":"Zhang L, et\u00a0al. Prevalence of depression and anxiety in systemic lupus erythematosus: a systematic review and meta-analysis. BMC Psychiatry. 2017;17(1):70.","journal-title":"BMC Psychiatry"},{"key":"872_CR7","unstructured":"FDA. Drug Development and Drug Interactions. 05\/12\/2022. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers#table3-1. Accessed 20 Nov 2023."},{"issue":"14","key":"872_CR8","first-page":"1127","volume":"21","author":"S Rendic","year":"2020","unstructured":"Rendic S, Guengerich FP. Metabolism and interactions of chloroquine and hydroxychloroquine with human cytochrome P450 enzymes and drug transporters. Curr Drug Metab. 2020;21(14):1127\u201335.","journal-title":"Curr Drug Metab"},{"issue":"10","key":"872_CR9","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s00228-020-02928-7","volume":"76","author":"X Li","year":"2020","unstructured":"Li X, et\u00a0al. The parent drugs chloroquine and hydroxychloroquine do not inhibit human CYP3A activity in vitro. Eur J Clin Pharmacol. 2020;76(10):1481\u20132.","journal-title":"Eur J Clin Pharmacol"},{"key":"872_CR10","doi-asserted-by":"crossref","unstructured":"Paludetto MN, et al. Hydroxychloroquine is metabolized by CYP2D6, CYP3A4, and CYP2C8, and inhibits CYP2D6, while\nits metabolites also inhibit CYP3A in vitro. Drug Metab Dispos. 2023;51:293\u2013305.","DOI":"10.1124\/dmd.122.001018"},{"issue":"2","key":"872_CR11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/cpdd.999","volume":"11","author":"F Stoll","year":"2022","unstructured":"Stoll F, et\u00a0al. Effect of pantoprazole on the absorption of hydroxychloroquinea a randomized drug-drug interaction trial in healthy adults. Clin Pharmacol Drug Dev. 2022;11(2):285\u201390.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"6","key":"872_CR12","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1046\/j.1365-2125.2000.00197.x","volume":"49","author":"M Somer","year":"2000","unstructured":"Somer M, et\u00a0al. Influence of hydroxychloroquine on the bioavailability of oral metoprolol. Br J Clin Pharmacol. 2000;49(6):549\u201354.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"872_CR13","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1186\/s13063-020-04476-y","volume":"21","author":"F Stoll","year":"2020","unstructured":"Stoll F, et\u00a0al. Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Corona Virus Disease-19 (Covid-19): a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):584.","journal-title":"Trials"},{"issue":"6","key":"872_CR14","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/clpt.2013.27","volume":"93","author":"B Halama","year":"2013","unstructured":"Halama B, et\u00a0al. A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions. Clin Pharmacol Ther. 2013;93(6):564\u201371.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"872_CR15","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s40262-020-00862-6","volume":"59","author":"M Vay","year":"2020","unstructured":"Vay M, et\u00a0al. Oral yohimbine as a new probe drug to predict CYP2D6 activity: results of a fixed-sequence phase I trial. Clin Pharmacokinet. 2020;59(7):927\u201339.","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"872_CR16","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00228-010-0878-2","volume":"66","author":"S Katzenmaier","year":"2010","unstructured":"Katzenmaier S, Markert C, Mikus G. Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam. Eur J Clin Pharmacol. 2010;66(11):1137\u201341.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"872_CR17","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/clpt.2011.164","volume":"90","author":"S Katzenmaier","year":"2011","unstructured":"Katzenmaier S, et\u00a0al. Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy. Clin Pharmacol Ther. 2011;90(5):666\u201373.","journal-title":"Clin Pharmacol Ther"},{"issue":"16","key":"872_CR18","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.4155\/bio-2019-0129","volume":"11","author":"M Vay","year":"2019","unstructured":"Vay M, et\u00a0al. Quantification of microdosed oral yohimbine and its major metabolite in human plasma in the picogram range. Bioanalysis. 2019;11(16):1459\u201367.","journal-title":"Bioanalysis"},{"key":"872_CR19","unstructured":"EMA. ICH guideline M10 on bioanalytical method validation and study sample analysis. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-m10-bioanalytical-method-validation-step-5_en.pdf. Accessed 20 Nov 2023."},{"key":"872_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.106076","volume":"169","author":"J Weiss","year":"2022","unstructured":"Weiss J, et\u00a0al. Does the circulating ketoconazole metabolite N-deacetyl ketoconazole contribute to the drug-drug interaction potential of the parent compound? Eur J Pharm Sci. 2022;169: 106076.","journal-title":"Eur J Pharm Sci"},{"key":"872_CR21","unstructured":"EMA. Guideline on the investigation of bioequivalence. 2010. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf. Accessed 20 Nov 2023."},{"issue":"2","key":"872_CR22","first-page":"51","volume":"34","author":"H Bliesath","year":"1996","unstructured":"Bliesath H, et\u00a0al. Pantoprazole does not interact with nifedipine in man under steady-state conditions. Int J Clin Pharmacol Ther. 1996;34(2):51\u20135.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1 Suppl","key":"872_CR23","first-page":"S31","volume":"34","author":"VW Steinijans","year":"1996","unstructured":"Steinijans VW, et\u00a0al. Lack of pantoprazole drug interactions in man: an updated review. Int J Clin Pharmacol Ther. 1996;34(1 Suppl):S31-50.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"8","key":"872_CR24","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1124\/dmd.32.8.821","volume":"32","author":"XQ Li","year":"2004","unstructured":"Li XQ, et\u00a0al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32(8):821\u20137.","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"872_CR25","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s00228-022-03406-y","volume":"78","author":"MH Breithaupt","year":"2022","unstructured":"Breithaupt MH, et\u00a0al. Oral bioavailability of microdoses and therapeutic doses of midazolam as a 2-dimensionally printed orodispersible film in healthy volunteers. Eur J Clin Pharmacol. 2022;78(12):1965\u201372.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"872_CR26","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0009-9236(96)90177-0","volume":"59","author":"KE Thummel","year":"1996","unstructured":"Thummel KE, et\u00a0al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther. 1996;59(5):491\u2013502.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"872_CR27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.phrs.2003.10.010","volume":"49","author":"L Calabresi","year":"2004","unstructured":"Calabresi L, et\u00a0al. Pharmacokinetic interactions between omeprazole\/pantoprazole and clarithromycin in health volunteers. Pharmacol Res. 2004;49(5):493\u20139.","journal-title":"Pharmacol Res"},{"issue":"1","key":"872_CR28","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40360-020-00433-2","volume":"21","author":"D Ochoa","year":"2020","unstructured":"Ochoa D, et\u00a0al. Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole. BMC Pharmacol Toxicol. 2020;21(1):54.","journal-title":"BMC Pharmacol Toxicol"},{"key":"872_CR29","unstructured":"Summary of Product Characteristics, Pantoprazol 40 mg magensaftresistente Tabletten. Hexal, Holzkirchen. 2021."},{"key":"872_CR30","unstructured":"Summary of Product Characteristics, Quensyl\u00ae 200 mg Filmtabletten. Sanofi-Aventis, Frankfurt. 2022."},{"issue":"1","key":"872_CR31","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/art.39402","volume":"68","author":"JY Lee","year":"2016","unstructured":"Lee JY, et\u00a0al. Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2016;68(1):184\u201390.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"872_CR32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/j.1552-4604.1986.tb02903.x","volume":"26","author":"LD Bornemann","year":"1986","unstructured":"Bornemann LD, et\u00a0al. Influence of food on midazolam absorption. J Clin Pharmacol. 1986;26(1):55\u20139.","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"872_CR33","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/cpdd.924","volume":"10","author":"A Huppertz","year":"2021","unstructured":"Huppertz A, et\u00a0al. Differential effect of a continental breakfast on tacrolimus formulations with different release characteristics. Clin Pharmacol Drug Dev. 2021;10(8):899\u2013907.","journal-title":"Clin Pharmacol Drug Dev"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-023-00872-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-023-00872-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-023-00872-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T18:13:47Z","timestamp":1704910427000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-023-00872-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,20]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["872"],"URL":"https:\/\/doi.org\/10.1007\/s13318-023-00872-2","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,20]]},"assertion":[{"value":"20 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No author reports a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The trial was approved by the responsible Ethics Committee of the Medical Faculty of Heidelberg University, Germany (ethical approval number AFmo-265\/2020).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Participants were fully informed and gave their written consent prior to any trial-related procedures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}